The device was received and analyzed.Prior to the analysis of the device, the manufacturing process for this pacemaker was re-investigated and all production steps were performed accordingly.There was no sign of any inconsistency during the manufacturing process.Particularly the final acceptance test proved the device functions to be as specified.Upon receipt, the device was interrogated showing an alert on the programming device as mentioned in the complaint description.The eri battery status was triggered on (b)(6) 2021.The memory content of the device was thoroughly analyzed.The battery voltage and current consumption were found to be normal and as expected.The analysis further showed that a large amount of home monitoring transmission retries were documented in the device data, which can lead to a temporary increase of current consumption and a noticeable decrease of time to eri.In general, the current consumption of the device is influenced by different factors, which may lead to noticeable changes of tte indication.Such factors are, for instance, changes in lead impedance values or the programmed parameters, a prolonged follow-up session or even a large amount of hm transmission retries.The amount of charge taken from the battery was verified.The battery condition was found to be normal and as expected.After eri activation, the battery voltage temporarily recovered to a value above the eri threshold.This does not represent a battery malfunction but results in a displayed message during interrogation.Next, the pacemaker was subjected to an electrical analysis.The ability of the device to deliver therapies was verified.The anti-bradycardia pacing pulses proved to be normal and in amplitude and frequency as programmed.In summary, the pacemaker was fully functional.The battery condition was found to be normal and as expected.The analysis did not reveal any sign of a material or manufacturing problem.
|